These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8569537

  • 41. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H, Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [Abstract] [Full Text] [Related]

  • 42. Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria.
    Cambau E, Sougakoff W, Jarlier V.
    FEMS Microbiol Lett; 1994 Feb 01; 116(1):49-54. PubMed ID: 8132154
    [Abstract] [Full Text] [Related]

  • 43. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M, Abergel C, Raoult D.
    Antimicrob Agents Chemother; 2001 Jul 01; 45(7):2098-105. PubMed ID: 11408229
    [Abstract] [Full Text] [Related]

  • 44. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
    Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S.
    Antimicrob Agents Chemother; 1991 Aug 01; 35(8):1647-50. PubMed ID: 1656869
    [Abstract] [Full Text] [Related]

  • 45. DNA gyrase as a drug target.
    Maxwell A.
    Biochem Soc Trans; 1999 Feb 01; 27(2):48-53. PubMed ID: 10093705
    [No Abstract] [Full Text] [Related]

  • 46. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
    Chen JY, Siu LK, Chen YH, Lu PL, Ho M, Peng CF.
    Microb Drug Resist; 2001 Feb 01; 7(1):47-53. PubMed ID: 11310803
    [Abstract] [Full Text] [Related]

  • 47. Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.
    Masecar BL, Robillard NJ.
    Antimicrob Agents Chemother; 1991 May 01; 35(5):898-902. PubMed ID: 1649573
    [Abstract] [Full Text] [Related]

  • 48. Serotyping of quinolone-resistant Neisseria gonorrhoeae isolates with alterations in GyrA and ParC.
    Deguchi T, Yasuda M, Maeda SI, Saito I, Kawada Y.
    J Antimicrob Chemother; 1998 Mar 01; 41(3):418-20. PubMed ID: 9578173
    [No Abstract] [Full Text] [Related]

  • 49. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae.
    Deguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, Ezaki T, Saito I, Kawada Y.
    Antimicrob Agents Chemother; 1995 Feb 01; 39(2):561-3. PubMed ID: 7726535
    [Abstract] [Full Text] [Related]

  • 50. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli.
    Bachoual R, Tankovic J, Soussy CJ.
    Microb Drug Resist; 1998 Feb 01; 4(4):271-6. PubMed ID: 9988045
    [Abstract] [Full Text] [Related]

  • 51. gyrA mutations in quinolone-resistant isolates of the fish pathogen Aeromonas salmonicida.
    Oppegaard H, Sørum H.
    Antimicrob Agents Chemother; 1994 Oct 01; 38(10):2460-4. PubMed ID: 7840589
    [Abstract] [Full Text] [Related]

  • 52. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.
    Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V.
    J Infect Dis; 1994 Aug 01; 170(2):479-83. PubMed ID: 8035042
    [Abstract] [Full Text] [Related]

  • 53. Escherichia coli DNA gyrase: genetic analysis of gyrA and gyrB mutations responsible for thermosensitive enzyme activity.
    Oram M, Kuroda R, Fisher LM.
    FEBS Lett; 1992 Nov 02; 312(1):61-5. PubMed ID: 1330681
    [Abstract] [Full Text] [Related]

  • 54. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M, Yonezawa M, Kurose S, Futakuchi N, Matsubara N, Watanabe Y, Narita H.
    J Antimicrob Chemother; 1996 Sep 02; 38(3):543-6. PubMed ID: 8889728
    [Abstract] [Full Text] [Related]

  • 55. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T, Tanaka M, Yamaguchi A, Sato K.
    Antimicrob Agents Chemother; 2001 Aug 02; 45(8):2263-8. PubMed ID: 11451683
    [Abstract] [Full Text] [Related]

  • 56. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J, Robicsek A, Hooper DC.
    Antimicrob Agents Chemother; 2006 Feb 02; 50(2):600-6. PubMed ID: 16436716
    [Abstract] [Full Text] [Related]

  • 57. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
    Navia MM, Ruiz J, Ribera A, de Anta MT, Vila J.
    J Antimicrob Chemother; 1999 Dec 02; 44(6):743-8. PubMed ID: 10590274
    [Abstract] [Full Text] [Related]

  • 58. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
    Heddle JG, Lu T, Zhao X, Drlica K, Maxwell A.
    J Mol Biol; 2001 Jun 22; 309(5):1219-31. PubMed ID: 11399091
    [Abstract] [Full Text] [Related]

  • 59. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR, Foster SR, Maxwell A.
    J Mol Biol; 2000 Jul 14; 300(3):481-91. PubMed ID: 10884345
    [Abstract] [Full Text] [Related]

  • 60. Detection of ciprofloxacin resistance mutations in Campylobacter jejuni gyrA by nonradioisotopic single-strand conformation polymorphism and direct DNA sequencing.
    Charvalos E, Peteinaki E, Spyridaki I, Manetas S, Tselentis Y.
    J Clin Lab Anal; 1996 Jul 14; 10(3):129-33. PubMed ID: 8731499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.